Edition:
United Kingdom

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

86.58USD
23 Feb 2018
Change (% chg)

$0.02 (+0.02%)
Prev Close
$86.56
Open
$86.59
Day's High
$86.59
Day's Low
$86.55
Volume
388,568
Avg. Vol
908,879
52-wk High
$86.75
52-wk Low
$19.62

Chart for

About

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to... (more)

Overall

Beta: --
Market Cap(Mil.): $4,869.33
Shares Outstanding(Mil.): 111.66
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

France's Cellectis wins U.S patents for gene editing technology

PARIS The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

13 Feb 2018

France's Cellectis wins U.S patents for gene editing technology

PARIS, Feb 13 The United States has granted French cell therapy group Cellectis two patents to deploy a technology known as CRISPR in T cells, which play a key role in the immune response to cancer, the company said on Tuesday.

13 Feb 2018

BRIEF-Celgene Corp Commences Tender Offer For Juno Therapeutics

* CELGENE CORPORATION COMMENCES TENDER OFFER FOR JUNO THERAPEUTICS, INC.

02 Feb 2018

GRAPHIC-Biotech M&A explodes with $27.5 bln of January deals

LONDON, Jan 31 Biotech deal-making is the hottest in more than a decade with $27.5 billion of transactions agreed this month and bankers reporting an above-average number of discussions that could lead to fresh activity through 2018.

31 Jan 2018

Bluebird CAR-T still top Celgene priority after Juno deal

Celgene Corp said on Thursday that a pending $9 billion purchase of Juno Therapeutics in no way alters its focus on its partnership with Juno rival bluebird bio .

25 Jan 2018

UPDATE 3-Bluebird CAR-T still top Celgene priority after Juno deal

Jan 25 Celgene Corp said on Thursday that a pending $9 billion purchase of Juno Therapeutics in no way alters its focus on its partnership with Juno rival bluebird bio.

25 Jan 2018

Celgene to buy Juno for $9 billion to boost cancer pipeline

Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video

22 Jan 2018

Stocks hit record as senators reach deal to end shutdown

U.S. stocks advanced on Monday as each of Wall Street's main scored records in the wake of a deal by U.S. senators to end the federal government shutdown. | Video

22 Jan 2018

US STOCKS-Stocks hit record as U.S. senators reach deal to end shutdown

* Dow up 0.55 pct, S&P 500 up 0.81 pct, Nasdaq up 0.98 pct (Updates to market close)

22 Jan 2018

Deals of the day-Mergers and acquisitions

Jan 22 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Monday:

22 Jan 2018

Earnings vs. Estimates